Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients

Official title

Low-dose Teclistamab As Consolidation in the First-line Treatment of Patients with Newly Diagnosed Multiple Myeloma.

Overview

This single-arm, open-label study aims to determine the efficacy and safety of low-dose, limited-duration teclistamab as a consolidation scheme in newly diagnosed multiple myeloma (NDMM) patients.

Detailed description

This single-arm, open-label study aims to determine the efficacy and safety of low-dose (1.0 mg/kg), limited-duration teclistamab as a consolidation scheme in newly diagnosed multiple myeloma (NDMM) patients after 3 (three) VRd cycles as induction therapy.

Patients with MMND who meet the established inclusion criteria will be invited to participate. A single-arm phase 2 study will be conducted in the Hematology Department of the University Hospital, where an induction schedule of 3 cycles of bortezomib, lenalidomide, and dexamethasone (VRd) will be administered followed by consolidation with 4 therapeutic doses of teclistamab at 1.0 mg/kg subcutaneously. Four weeks after the last dose of teclistamab, the clinical response will be assessed according to standard International Myeloma Working Group (IMWG) criteria. Those with a complete response (CR) or better will be assessed for measurable residual disease (MRD) with multiparametric flow cytometry with a sensitivity of 10\^6. Patients with CR and negative MRD will be kept under active surveillance for 18 months, while those with positive MRD or high cytogenetic risk will be offered biweekly bortezomib as maintenance. On the other hand, patients with very good partial response (VGPR) or worse will be offered 1-2 additional therapeutic doses of teclistamab and reevaluated 4 weeks after the last dose. Finally, patients who do not achieve CR will exit the study and will continue their management according to the standard of care recommended by their treating physician.

Interventions

• Drug Low-dose teclistamab
  NDMM patients will receive VRd 3x cicles followed by low dose teclistamab.

Primary outcome measures

• To determine general response [Time frame: 18 months after last teclistamab dose]

Secondary outcome measures (2)

• To determine response duration [Time frame: Up to 18 months after last teclistamab dose]
• Adverse events [Time frame: Through the study completion and up to 18 months after last teclistamab dose]

Eligibility criteria

Inclusion criteria

• ≥18 years of age.
• Newly diagnosed multiple myeloma.
• Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 0 or 1.
• Women of childbearing potential must have a negative serum pregnancy test prior to starting treatment and agree to use a highly effective method of contraception, such as a hormonal method that inhibits ovulation, an intrauterine device, or a vasectomy partner.
• Males: agree to use a highly effective contraceptive method, such as a male condom or vasectomy.

Exclusion criteria

• History of previous treatment for MM.
• Active central nervous system (CNS) involvement or clinical signs of meningeal involvement of multiple myeloma.
• Plasma cell leukemia, Waldenström's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes) or AL amyloidosis.
• Severe active infection secondary to viruses, bacteria or fungi.
• Pulmonary disease requiring supplemental oxygen.
• History of allogeneic or autologous hematopoietic cell transplantation.
• Vaccination with live attenuated virus in the 4 weeks prior to teclistamab administration.
• Major surgery during the 2 weeks prior to the first dose or absence of complete recovery from surgery.
• Presence of other concomitant malignancy.
• Hepatitis B and C virus infection or human immunodeficiency virus (HIV) infection.
• Cerebrovascular events or seizures in the last 6 months.
• Congestive heart failure class III-IV according to NYHA (New York Heart Association Stage).
• Acute myocardial infarction or history of coronary revascularization surgery in the last 6 months.
• Women of childbearing age: active pregnancy prior to the first administration of treatment.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

Mexico · 1 center

• Hospital Universitario Dr. Jose E. Gonzalez — Monterrey

Publications

• Girgis S, Lin SXW, Pillarisetti K, Banerjee A, Stephenson T, Ma X, Shetty S, Yang TY, Hilder BW, Jiao Q, Hanna B, Adams HC 3rd, Sun YN, Sharma A, Smit J, Infante JR, Goldberg JD, Elsayed Y. Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma. Target Oncol. 2022 Jul;17(4):433-439. doi: 10.1007/s11523-022-00893-y. Epub 2022 Jun 24. PMID 35749004
• Usmani SZ, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Rosinol L, Chari A, Bhutani M, Karlin L, Benboubker L, Pei L, Verona R, Girgis S, Stephenson T, Elsayed Y, Infante J, Goldberg JD, Banerjee A, Mateos MV, Krishnan A. Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-la PMID 34388396

Identifiers

NCT: NCT06758375 · HE24-00015

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗